Non-Interventional Study to Examine Rituximab Treatment in Follicular Lymphoma Participants

• Status: Completed
• Trial end date: 2014-06-01
• Target enrollment: 0
• Participant gender: All

Summary

It is a non-interventional study with a duration of approximately 24 months per participant to investigate the therapeutic efficiency, safety and treatment regimens of Rituximab maintenance therapy in daily routine in participants with previously untreated, relapsed or refractory cluster of differentiation 20 (CD20)-positive follicular lymphoma (FL) in clinical practice.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hoffmann-La Roche
• Treatments: Rituximab

Criteria

Inclusion Criteria:

• Age over 18 years

• Previously untreated, relapsed or refractory CD 20-positive FL

• Responding to rituximab containing induction therapy (complete response [CR] or partial response [PR])

• To receive rituximab maintenance therapy (decision taken by doctor prior to and independent of this non-interventional study)

• No ineligibility for rituximab

Exclusion Criteria:

Not Applicable (NA)